ACADIA Pharmaceuticals (NASDAQ:ACAD) is an undervalued small-cap stock that is developing advanced technology related to two common ailments that cause psychosis in the elderly, Alzheimer's and Parkinson's. Additionally, the company is using the same platform to develop a treatment for schizophrenia. Longer term projects include treatments for chronic pain and glaucoma and broader treatments for Parkinson's disease. Based on market and company research a price target of $25 for sometime between July 2014 and December 2014 is a realistic and achievable goal for the stock.
THE AGING POPULATION DRIVES A GROWING MARKET
There is no way around the fact that in major industrialized nations the population is aging and afflictions and diseases that affect this demographic are becoming...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|